Abstract
Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95% confidence interval/CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.
| Original language | English |
|---|---|
| Pages (from-to) | 383-393 |
| Number of pages | 11 |
| Journal | APMIS |
| Volume | 123 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2015 May 1 |
Fingerprint
Keywords
- Breast cancer
- ErbB3
- Meta-analysis
- Prognosis
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Microbiology (medical)
- Immunology and Allergy
Cite this
Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression. / Kim, Hyun Jung; Kim, Aeree; Ahn, Hyeong Sik; Ahn, Il Min; Choi, Jinhyuk; Chang, Hyeyoon.
In: APMIS, Vol. 123, No. 5, 01.05.2015, p. 383-393.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression
AU - Kim, Hyun Jung
AU - Kim, Aeree
AU - Ahn, Hyeong Sik
AU - Ahn, Il Min
AU - Choi, Jinhyuk
AU - Chang, Hyeyoon
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95% confidence interval/CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.
AB - Prognostic value of ErbB3 in human breast cancer is still controversial. However, the roles of ErbB3 receptors in drug resistance are recently emerging. The objective of this study was to evaluate the relationship between ErbB3 expression and survival of breast cancer via meta-analysis. A systematic literature search was conducted and 32 potentially relevant studies were included in the meta-analysis. Outcomes presented in searched literatures can be classified as disease free survival (DFS), overall survival (OS), and progress free survival (PFS) values. Meta-analysis was performed for each group. Results showed no statistically significant difference in survival. The overall hazard ratio of PFS, DFS, and OS of ErbB3 expression was 1.40 [95% confidence interval/CI (0.51, 3.83)], 1.07 [95% CI (0.82, 1.40)], and 1.15 [95% CI (0.91, 1.44)], respectively. Subgroup analysis according to ErbB2 receptor status, ErbB3 assessment methods (immunohistochemistry/IHC vs non-IHC), and analysis type (multivariate and univariate analysis) were performed. No significant association was found. Using various assessment methods and patient populations, our results revealed that there was no significant correlation between ErbB3 expression and breast cancer survival. Further studies on heterodimers of ErbB3 and other molecular markers involved in ErbB3 related pathway are merited.
KW - Breast cancer
KW - ErbB3
KW - Meta-analysis
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84928226460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928226460&partnerID=8YFLogxK
U2 - 10.1111/apm.12371
DO - 10.1111/apm.12371
M3 - Article
C2 - 25912128
AN - SCOPUS:84928226460
VL - 123
SP - 383
EP - 393
JO - Acta pathologica et microbiologica Scandinavica
JF - Acta pathologica et microbiologica Scandinavica
SN - 0365-5555
IS - 5
ER -